PREhabilitation in Patients Awaiting Acute Inpatient Cardiac SurgEry
Launched by UNIVERSITY OF HULL · Feb 16, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called PREhabilitation in Patients Awaiting Acute Inpatient Cardiac Surgery, is exploring a program designed to help patients prepare for heart surgery. The study aims to see how practical and acceptable this prehabilitation program is for patients who are waiting for procedures related to various heart conditions, such as aortic valve disease or coronary artery disease. Researchers will look at how many patients can participate, how well they can complete the program, and any challenges they might face. They will also measure things like walking ability, strength, quality of life, and safety during the study.
To be eligible for this trial, patients must be over 18 years old and scheduled for heart surgery at Castle Hill Hospital. However, those who cannot participate due to serious health issues, cognitive challenges, or those who are too close to their surgery date may not be included. Participants can expect to engage in activities that help prepare their bodies for surgery and will be asked for their feedback to improve the program. This trial is currently recruiting participants and aims to make heart surgery safer and more effective for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients over the age of 18 scheduled for acute cardiac surgery in CHH will be given consideration to participate in this clinical trial.
- Exclusion Criteria:
- • Patients who are unable or unwilling to participate in any of the elements of prehabilitation will be excluded. These include those that have cognitive disability (including unconsciousness), cardiac or clinical instability, functional or anatomical impairment which impairs ability to participate, language barrier or patient refusal. Patients that have impending surgery within 72 hours of arrival to hospital will be excluded. Patients who are awaiting surgery in district hospitals or outside of Castle Hill Hospital will be excluded. A non-exhaustive list of exclusion criteria is included below.
- Cardiac/ clinical instability such as:
- • Recurrent unstable angina/ crescendo angina
- • Untreated decompensated heart failure
- • Malignant arrhythmias awaiting treatment
- • Resting tachycardia (HR\>100 bpm)
- • Left ventricular outflow obstruction such as Aortic Stenosis with pre-syncopal or syncopal symptoms
- • Unresolved acute pericarditis or myocarditis
- • Second or third degree heart block without pacemaker
- • Aortic Dissection
- • Myxoma
- Functional/ anatomical impairment such as:
- • Severe musculoskeletal conditions that would prohibit exercise
- • Amputees
- • Registered blind
About University Of Hull
The University of Hull is a leading academic institution in the UK, renowned for its commitment to advancing research and innovation in various fields, including healthcare and clinical sciences. With a strong emphasis on interdisciplinary collaboration, the university fosters an environment that promotes cutting-edge clinical trials aimed at improving patient outcomes and advancing medical knowledge. Its research initiatives are supported by a diverse team of experts and state-of-the-art facilities, positioning the University of Hull as a key contributor to the development of effective treatments and healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hull, , United Kingdom
Patients applied
Trial Officials
Sarah Raut
Principal Investigator
University of Hull
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported